Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is...
27 insider purchases on record · latest filing 2024-12-26.
Insiders have also filed 379 sale transactions at FATE.